Fabrication of Antibacterial Poly(Vinyl Alcohol) Nanocomposite Films Containing Dendritic Polymer Functionalized Multi-Walled Carbon Nanotubes

A series of poly(vinyl alcohol) (PVA) nanocomposite films containing quaternized hyperbranched polyethyleneimine (PEI) functionalized multi-walled carbon nanotubes (ox-CNTs@QPEI) are prepared by solvent casting technique. The modified carbon-based material exhibits high aqueous solubility, due to the hydrophilic character of the functionalized hyperbranched dendritic polymer. The quaternized PEI successfully wraps around nanotube walls as polycations provide electrostatic repulsion. Various contents of ox-CNTs@QPEI ranging from 0.05 to 1.0% w/w were employed to prepare functionalized PVA nanocomposites. The developed films exhibit adequate optical transparency, improved mechanical properties and extremely high antibacterial behavior due to the excellent dispersion of the functionalized CNTs into the PVA matrix

A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity

Drug delivery systems that target subcellular organelles and, in particular, mitochondria are considered to have great potential in treating disorders that are associated with mitochondrial dysfunction, including cancer or neurodegenerative diseases. To this end, a novel hyperbranched mitochondriotropic nanocarrier was developed for the efficient co-delivery of two different (both in chemical and pharmacological terms) bioactive compounds. The carrier is based on hyperbranched poly(ethyleneimine) functionalized with triphenylphosphonium groups that forms ~100 nm diameter nanoparticles in aqueous media and can encapsulate doxorubicin (DOX), a well-known anti-cancer drug, and chloroquine (CQ), a known chemosensitizer with arising potential in anticancer medication. The anticancer activity of this system against two aggressive DOX-resistant human prostate adenocarcinoma cell lines and in in vivo animal studies was assessed. The co-administration of encapsulated DOX and CQ leads to improved cell proliferation inhibition at extremely low DOX concentrations (0.25 μΜ). In vivo experiments against DU145 human prostate cancer cells grafted on immunodeficient mice resulted in tumor growth arrest during the three-week administration period and no pervasive side effects. The findings put forward the potential of such targeted low dose combination treatments as a therapeutic scheme with minimal adverse effects